ImmunityBio (IBRX) Stock Jumps 20% as FDA Clears Path for Bladder Cancer Treatment

TLDR ImmunityBio stock jumped 19.8% in premarket trading after productive FDA meeting about ANKTIVA bladder cancer treatment FDA recommended submitting additional information for supplemental application but did not request new clinical trials Long-term data shows approximately 96% bladder cancer-specific survival and over 80% bladder preservation at three years Company plans to provide requested FDA information [...]

The post ImmunityBio (IBRX) Stock Jumps 20% as FDA Clears Path for Bladder Cancer Treatment appeared first on Blockonomi.